Haite Biotech announced that the company's clinical trial application for injectable epneamin for unresectable or metastatic classic chondrosarcoma indications was accepted by the China Drug Administration. Epnimine for injection is an innovative national Class I recombinant protein drug independently developed by the company. It is also the world's first and only marketed death receptor 4/death receptor 5 agonist.

Haite Biotech announced that the company's clinical trial application for injectable epneamin for unresectable or metastatic classic chondrosarcoma indications was accepted by the China Drug Administration. Epneamin for injection is an innovative national Class I recombinant protein drug independently developed by the company. It is also the world's first and only marketed death receptor 4/death receptor 5 agonist.